Bottoni, Patrizia
 Distribuzione geografica
Continente #
NA - Nord America 2.155
AS - Asia 1.564
EU - Europa 1.395
SA - Sud America 271
AF - Africa 34
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 2
Totale 5.425
Nazione #
US - Stati Uniti d'America 2.097
SG - Singapore 632
CN - Cina 460
DE - Germania 414
BR - Brasile 209
SE - Svezia 203
UA - Ucraina 203
VN - Vietnam 128
FR - Francia 116
IT - Italia 100
GB - Regno Unito 77
IE - Irlanda 72
IN - India 66
FI - Finlandia 59
TR - Turchia 54
ID - Indonesia 49
RU - Federazione Russa 48
CA - Canada 36
JP - Giappone 32
BD - Bangladesh 31
HK - Hong Kong 25
AR - Argentina 23
BE - Belgio 16
IQ - Iraq 16
KR - Corea 16
ES - Italia 15
NL - Olanda 14
MX - Messico 10
VE - Venezuela 10
PK - Pakistan 9
ZA - Sudafrica 9
CH - Svizzera 8
PL - Polonia 7
SA - Arabia Saudita 7
CZ - Repubblica Ceca 6
EC - Ecuador 6
MA - Marocco 6
RO - Romania 6
AT - Austria 5
CL - Cile 5
MY - Malesia 5
PY - Paraguay 5
BO - Bolivia 4
CO - Colombia 4
DZ - Algeria 4
IL - Israele 4
IR - Iran 4
KE - Kenya 4
PT - Portogallo 4
UZ - Uzbekistan 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
AU - Australia 3
DK - Danimarca 3
EG - Egitto 3
UY - Uruguay 3
AZ - Azerbaigian 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
GE - Georgia 2
HN - Honduras 2
HU - Ungheria 2
KZ - Kazakistan 2
LT - Lituania 2
LU - Lussemburgo 2
NG - Nigeria 2
NO - Norvegia 2
PE - Perù 2
PH - Filippine 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BG - Bulgaria 1
BH - Bahrain 1
BW - Botswana 1
BY - Bielorussia 1
EU - Europa 1
GA - Gabon 1
GR - Grecia 1
HR - Croazia 1
JM - Giamaica 1
JO - Giordania 1
KG - Kirghizistan 1
LB - Libano 1
LV - Lettonia 1
ME - Montenegro 1
NP - Nepal 1
NZ - Nuova Zelanda 1
OM - Oman 1
PA - Panama 1
PS - Palestinian Territory 1
QA - Qatar 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
TN - Tunisia 1
Totale 5.425
Città #
Singapore 335
Chandler 294
Ashburn 232
San Jose 181
Jacksonville 103
Beijing 79
San Mateo 76
Nanjing 72
New York 71
Dublin 68
The Dalles 53
Wilmington 48
Ann Arbor 46
Hefei 43
Redmond 43
Izmir 42
Los Angeles 41
Jakarta 40
Woodbridge 40
Lauterbourg 38
Dearborn 37
Hanoi 37
Houston 37
Ho Chi Minh City 36
Boston 31
Chicago 30
Lawrence 30
Bremen 24
Hong Kong 23
Moscow 23
Tokyo 23
Frankfurt am Main 22
Cattolica 21
São Paulo 21
Fairfield 20
Seattle 20
Detroit 18
Boardman 16
Kent 16
Kunming 16
Montreal 15
Mountain View 15
Nanchang 15
Helsinki 14
Nürnberg 14
Shanghai 14
Zhengzhou 14
Redwood City 13
Brussels 12
London 12
Munich 12
Hangzhou 11
Hebei 11
Rome 11
Seoul 11
Philadelphia 10
Pune 10
Shenyang 10
Brooklyn 9
Princeton 9
Santa Clara 9
Toronto 9
Guangzhou 8
Milan 8
Orem 8
University Park 8
Belo Horizonte 7
Buffalo 7
Cambridge 7
Dhaka 7
Düsseldorf 7
Lancaster 7
Paris 7
Atlanta 6
Chengdu 6
Dallas 6
Edinburgh 6
Madrid 6
Tianjin 6
Turku 6
Baghdad 5
Cardiff 5
Da Nang 5
Haiphong 5
Indiana 5
Jiaxing 5
Johannesburg 5
Simi Valley 5
Zurich 5
Biên Hòa 4
Brasília 4
Changsha 4
Curitiba 4
Goiânia 4
Lansing 4
Lanzhou 4
Littleton 4
Marseille 4
Norwalk 4
Ottawa 4
Totale 2.918
Nome #
Neuron-Specific Enolase as a Biomarker: Biochemical and Clinical Aspects 204
CA 19-9: Biochemical and Clinical Aspects 196
MITOCHONDRIAL DAMAGE AND METABOLIC COMPENSATORY MECHANISMS INDUCED BY HYPEROXIA IN U-937 CELL LINE. 186
3-(4-Aroyl-1-methyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides as a New Class of Synthetic Histone Deacetylase Inhibitors. 3. Discovery of Novel Lead Compounds Through Structure-Based Drug Design and Docking Studies 183
A proteomic approach to characterizing ciglitazone-induced cancer cell differentiation in Hep-G2 cell line 183
Neuron Specific Enolase as a biomarker: biochemical and clinical aspects 183
Mitochondrial proteomic approaches for new potential diagnostic and prognostic biomarkers in cancer 175
Mitochondria, ciglitazone and liver: a neglected interaction in biochemical pharmacology. 172
A two-dimensional electrophoresis preliminary approach to human hepatocarcinoma differentiation induced by PPAR-agonists. 161
Advances in Mitochondrial Medicine 160
A Critical Approach to Clinical Biochemistry of Chromogranin A 160
An update on pharmacological approaches to neurodegenerative diseases. 158
The Role of CA 125 as Tumor Marker: Biochemical and Clinical Aspects 156
Circulating tumour cells and cancer stem cells: A role for proteomics in defining the interrelationships between function,phenotype and differentiation with potential clinical applications. 154
The epithelial–mesenchymal transition in cancer: a potential critical topic for translational proteomic research 153
3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamides as a New Class of Synthetic Histone Deacetylase Inhibitors. 2. Effect of Pyrrole C2 and/or C4 Substitutions on Biological Activity 150
Bezafibrate Induces a Mitochondrial Derangement in Human Cell Lines. Intriguing Effects for a Peroxisome Proliferator. 150
CA 19-9: Biochemical and Clinical Aspects 148
Revisiting the Warburg effect in cancer cells with proteomics. The emergence of new approaches to diagnosis, prognosis and therapy 146
The role of mitochondria in pharmacotoxicology: a reevaluation of an old, newly emerging topic. 138
The proteomics of cancer stem cells. Potential clinical applications for innovative research in oncology 133
Cancer stem cells: the development of new cancer therapeutics 131
Modulation of cancer cell line differentiation: A neglected proteomic analysis with potential implications in pathophysiology, diagnosis, prognosis, and therapy of cancer. 131
Cancer Stem Cells: An Innovative Therapeutic Approach 129
Nitric oxide donor drugs: an update on pathophysiology and therapeutic potential. 126
Proteomic profiling of heat shock proteins: An emerging molecular approach with direct pathophysiological and clinical implications 125
Pharmacological modulation of nitric oxide release: new pharmacological perspectives, potential benefits and risks. 124
The role of CA 125 as tumor marker: biochemical and clinical aspects 123
A critical approach to clinical biochemistry of Chromogranin A 122
CA 19-9: Biochemical and Clinical Aspects 121
Cancer Stem Cells: Proteomic Approaches for New Potential Diagnostic and Prognostic Biomarkers 118
Advances in Heat Shock Proteomics: Towards a Better Understanding of the Physiology and Pathophysiology of Molecular Chaperones. 115
Glycolytic enzyme inhibitors in cancer treatment. 105
Exploring the connection unit in the HDAC inhibitor pharmacophore model: novel uracil-based hydroxamates. 100
Mitochondrial respiration and differentiation 98
Cellular respiration and dedifferentiation 93
Aroyl-Pyrrolyl Hydroxyamides: influence of pyrrole C4-phenylacetyl substitution on histone deacetilase inhibition 93
Aroyl-pyrrolyl hydroxyamides: influence of pyrrole C4-phenylacetyl substitution on histone deacetylase inhibition. 81
Mitochondria, PPARs, and Cancer: Is Receptor-Independent Action of PPAR Agonists a Key? 78
Totale 5.462
Categoria #
all - tutte 19.455
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.455


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202173 0 0 0 0 0 0 0 0 0 0 64 9
2021/2022343 29 39 4 39 21 16 8 56 8 17 37 69
2022/2023792 100 107 60 124 78 91 13 77 81 20 33 8
2023/2024319 19 95 4 7 12 62 13 13 4 13 45 32
2024/2025729 22 17 51 26 70 25 19 50 99 86 128 136
2025/20261.708 270 56 108 175 269 125 360 108 128 99 10 0
Totale 5.462